vancomycin

Vancomycin is a glycopeptide antibiotic that exerts its antibacterial activity by inhibiting the second stage of cell wall synthesis in susceptible bacteria. It also alters cell membrane permeability and selectively inhibits RNA synthesis. Vancomycin is commonly used to treat severe infections resistant to other antibiotics and is frequently employed in experimental studies to induce kidney injury models.

Vancomycin hydrochloride (Vancomycin HCl) is a glycopeptide antibiotic that targets Peptidoglycan in bacterial cell wall synthesis. Vancomycin hydrochloride is mainly used for the treatment of severe Gram-positive bacterial infections.

Norvancomycin hydrochloride (Desmethyl-vancomycin hydrochloride) is used as a treatment for endocarditis, osteomyelitis, pneumonia, sepsis, or soft tissue infections caused by Staphylococcus.

Ceftobiprole medocaril (BAL5788), the parenteral prodrug of Ceftobiprole, is a broad-spectrum cephalosporin effective against Methicillin-resistant Staphylococcus aureus (MRSA).

Ceftobiprole (Ro 63-9141) is a β-lactam antibacterial agent that exhibits potent bactericidal activity by binding to PBPs, inhibiting transpeptidation and formation of bacterial cell walls, leading to cell lysis and death, with a MIC90 value of 2 μg/mL against methicillin-resistant Staphylococcus aureus.

Tadalafil hydroxypiperidone is an impurity of Tadalafil -- a phosphodiesterase 5-inhibitor used for the treatment of erectile dysfunction.

Vancomycin prodrug (compound 13c) is a prodrug of Vancomycin. It exhibits antibacterial activity against Staphylococcus aureus (S. aureus) 330041, methicillin-resistant Staphylococcus aureus (MRSA) USA 300, and MRSA 3390, with minimum inhibitory concentrations (MICs) of 0.78 μM, 0.78 μM, and 1.56 μM, respectively. This prodrug can rapidly bind to the Cys-34 residue in plasma. It demonstrates therapeutic efficacy in mice infected with MRSA USA300, comparable to Vancomycin. As an albumin-binding, acid-sensitive prodrug, Vancomycin prodrug maintains Vancomycin's effectiveness against gram-positive bacterial infections while significantly reducing nephrotoxicity.

Vancomycin monohydrochloride is an amphoteric glycopeptide antibiotic that inhibits bacterial cell wall synthesis by binding to peptidoglycan.

Vancomycin-C13,D3 is a compound labeled with 13C and 2H. Vancomycin is a glycopeptide antibiotic that exerts antibacterial activity by altering cell membrane permeability and selectively inhibiting RNA synthesis.

Vancomycin-d12 TFA is a deuterated compound of Vancomycin TFA. Vancomycin TFA has a CAS number of 1404-90-6. Vancomycin is an antibiotic used to treat serious bacterial infections by stopping the growth of bacteria.

Vancomycin hydrochloride (Standard) is the standard substance of Vancomycin hydrochloride, and it is applicable for quantitative analysis, quality control, and related research in biochemical experiments. Vancomycin hydrochloride (Vancomycin HCl) is a glycopeptide antibiotic that targets Peptidoglycan in bacterial cell wall synthesis. Vancomycin hydrochloride is mainly used for the treatment of severe Gram-positive bacterial infections.

Vancomycin-[D10] Monoacetate Salt (Standard) is a reference standard of Vancomycin-[D10] Monoacetate Salt intended for quantitative analysis, quality control, and related biochemical research applications.

N-Demethylvancomycin is a glycopeptide antibiotic that has been found inNocardia orientalis.1It is active against several strains ofS. aureusandS. epidermidisin vitroandin vivo.2Formulations containing N-demethylvancomycin have been used in the treatment of bacterial infections. 1.Boeck, L.D., Mertz, F.P., Wolter, R.K., et al.N-demethylvancomycin, a novel antibiotic produced by a strain of Nocardia orientalis. Taxonomy and fermentationJ. Antibiot. (Tokyo)37(5)446-453(1984) 2.Hunt, A.H., Marconi, G.G., Elzey, T.K., et al.A51568A: N-demethylvancomycinJ. Antibiot. (Tokyo)37(8)917-919(1984)

N-Demethylvancomycin is a glycopeptide antibiotic that can be extracted from Nocardia orientalis and exhibits activity against various strains of Staphylococcus aureus and Staphylococcus epidermidis. It is utilized in research related to infections.

Ridinilazole (SMT19969) is a novel narrow-spectrum nonabsorbable antibiotic. Ridinilazole showed potent inhibition of C. difficile (MIC90=0.125 mg/L) and was markedly more active than either metronidazole (MIC90 = 8 mg/L) or vancomycin (MIC90 = 2 mg/L).

Tedizolid phosphate is a novel antibacterial prodrug. Tedizolid phosphate is a next-generation oxazolidinone with activity against both methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus spp. It also has effective activity a

Arcopilin A (compound Arcopilin A(1)) functions as an antibacterial agent with moderate inhibitory capabilities against fungal pathogens and Gram-positive bacteria, exhibiting IC 50 values of 8.9 μg/mL for KB-3-1 cells and 14 μg/mL for L929 cells. Notably, it can effectively eradicate preformed biofilms of Staphylococcus aureus. Additionally, Arcopilin A significantly boosts the efficacy of gentamicin (GM) and vancomycin (Vac), enhancing their activities by 115 and 31 times, respectively.

DNA Gyrase-IN-12 (Compound 6d) is an inhibitor of DNA gyrase. It exhibits antibacterial activity with MIC values ranging from 0.031 to 0.0625 μg/mL against Vancomycin-Intermediate Staphylococcus aureus (VISA) and Enterococcus faecium.

1-Amino-2,5-anhydro-1-deoxy-D-mannitol is a potent antibacterial compound effective against various Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE). Its application potential lies in its ability to combat common antibiotic-resistant bacterial infections effectively. 1-Amino-2,5-anhydro-1-deoxy-D-mannitol may emerge as a novel antimicrobial agent in clinical inhibition.

Anti-MRSA agent 19 (Compound 1) is an antibiotic that exhibits activity against Staphylococcus aureus. It is active against 40 clinical isolates from the CDC, representing diverse bacterial species with various resistance factors, including resistance to vancomycin, aminoglycoside/tetracycline, and oxazolidinone (median MIC=4 μg/mL).

V-161 is an orally active Na+-V-ATPase inhibitor with an IC50 of 144 nM. Under alkaline conditions, V-161 inhibits Enterococcus hirae and vancomycin-resistant Enterococcus faecium (VRE), with MIC values of 4 µg/mL for both. Additionally, V-161 can inhibit the colonization of VRE in the mouse small intestine.

KKL-40 is a small-molecule trans-translation inhibitor that exhibits significant antibacterial activity against Staphylococcus aureus.

MRSA/VRE-IN-1 (Compound 3e) is an inhibitor targeting methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE), with MIC/MBC values of 3.6/7.3 µM for VRE and 7.3/14.6 µM for MRSA. It is applicable in research focused on anti-infection studies.

Antibacterialagent 280 (Compound 7af) is an antimicrobial compound designed specifically to target methicillin-resistant and vancomycin-resistant Staphylococcus aureus (MRSA, VRSA). It shows promise for research applications involving S. aureus infections.